Valuation: ASKA Pharmaceutical Holdings Co.,Ltd.

Market Cap 57.64B 365M 324M 303M 276M 520M 35.15B 525M 3.64B 1.42B 17.97B 1.37B 1.34B P/E 2027 *
12.3x
P/E 2028 * 10.4x
Enterprise Value 57.64B 365M 324M 303M 276M 520M 35.15B 525M 3.64B 1.42B 17.97B 1.37B 1.34B EV / Sales 2027 *
0.79x
EV / Sales 2028 * 0.77x
Free-Float
64.59%
Yield 2027 *
3.2%
Yield 2028 * 3.45%
09-04 Metagen Therapeutics, Inc. announced that it has received ¥3.71 billion in funding from a group of investors CI
08-04 ASKA Pharmaceutical Holdings Co.,Ltd. Reports Earnings Results for the First Quarter Ended June 30, 2026 CI
06-25 Declaration of Voting Results by Asuka Pharmaceutical CI
05-27 Dalton Investment strongly oppose conditional activation of countermeasures announced by ASKA Pharmaceutical Holdings on May 25 RE
05-25 Aska pharmaceutical - plan to put to shareholders proposal on countermeasures against potential large-scale share purchase by Dalton and related parties RE
05-11 Asuka Pharmaceutical Opposes Nippon Active Value Fund Plc?s Shareholder Proposal for Board Changes at 2026 Annual Meeting CI
05-11 ASKA Pharmaceutical Holdings Co.,Ltd. Announces Change in Dividend Policy CI
05-11 ASKA Pharmaceutical Holdings Co.,Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2027 CI
05-11 ASKA Pharmaceutical Holdings Co.,Ltd. Proposes Year-End Dividend for Fiscal Year Ended March 31, 2026, Payable on June 25, 2026; Provides Dividend Guidance for End of Second Quarter of Fiscal Year Ending March 31, 2027 CI
05-11 ASKA Pharmaceutical Holdings Co.,Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2027 CI
05-11 ASKA Pharmaceutical Holdings Co.,Ltd. Announces Retirement of Kazuhiro Chiku as Audit & Supervisory Board Member, Effective June 24, 2026 CI
04-13 FTS AMBROSE HOLDINGS, INC. announced that it has received funding from ASKA Pharmaceutical Holdings Co.,Ltd. CI
03-24 Insilico Medicine And ASKA Pharmaceutical Enter Strategic Research Collaboration For Women's Health CI
1 day-1.02%
1 week-5.89%
Current month-1.26%
1 month-2.07%
3 months-13.69%
6 months-22.22%
Current year-0.39%
1 week 2,020
Extreme 2020
2,165
1 month 2,020
Extreme 2020
2,174
Current year 1,917
Extreme 1917
3,045
1 year 1,917
Extreme 1917
3,045
3 years 1,584
Extreme 1584
3,045
5 years 919
Extreme 919
3,045
10 years 776
Extreme 776
3,045
Manager TitleAgeSince
Chief Executive Officer - -
President 42 2025-06-23
Chief Administrative Officer - -
Director TitleAgeSince
Chairman 74 2025-06-23
Director/Board Member 67 2021-03-31
Director/Board Member 42 2021-03-31
Change 5-day change 1-year change 3-year change Capi.($)
-1.02%-5.89%-7.22%+25.62% 365M
-0.61%-3.43%+39.40%+112.31% 1,019B
-1.02%-5.60%+37.67%+65.02% 617B
+1.11%-0.58%+11.10%+77.28% 464B
+0.34%-3.01%+61.21%+40.71% 356B
-0.95%-4.05%+21.60%+39.37% 333B
-1.46%-2.89%+11.84%+24.60% 267B
-1.35%-5.43%-4.69%+8.40% 244B
-1.04%-2.79%+35.52%+51.34% 218B
-1.87%-4.10%+30.92%+95.33% 179B
Average -0.79%-3.64%+23.73%+54.00% 369.76B
Weighted average by Cap. -0.60%-3.33%+30.51%+68.95%

Financials

2027 *2028 *
Net sales 73.12B 463M 412M 384M 350M 660M 44.6B 666M 4.62B 1.8B 22.8B 1.74B 1.7B 74.96B 474M 422M 393M 359M 676M 45.71B 683M 4.73B 1.85B 23.37B 1.78B 1.74B
Net income 4.67B 29.55M 26.28M 24.5M 22.33M 42.12M 2.85B 42.52M 295M 115M 1.46B 111M 109M 5.52B 34.96M 31.09M 28.99M 26.42M 49.83M 3.37B 50.31M 349M 136M 1.72B 131M 129M
Net Debt - -
Logo ASKA Pharmaceutical Holdings Co.,Ltd.
ASKA Pharmaceutical Holdings Co Ltd is a Japan-based company primarily engaged in the pharmaceutical business. The Company has three business segments. The Pharmaceutical Business segment primarily manufactures and sells prescription pharmaceuticals. The Animal Health Business segment primarily manufactures and sells veterinary medicines, feed additives, and other products. The Overseas Business segment primarily manufactures and sells prescription pharmaceuticals overseas. The Company also engages in clinical testing and medical equipment businesses.
Employees
1,611
Date Price Change Volume
26-10-02 JP¥2,030.00 -1.02% 80,800
26-10-01 JP¥2,051.00 -0.24% 59,800
26-09-30 JP¥2,056.00 +0.44% 45,100
26-09-29 JP¥2,047.00 -3.67% 72,600
26-09-28 JP¥2,125.00 -1.48% 55,800
Trader
-
Investor
-
Global
-
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
2,030.00JPY
Average target price
2,400.00JPY
Spread / Average Target
+18.23%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 4886 Stock